一．团队名称
肿瘤免疫及靶向治疗团队
二．团队组成
本团队包含教授、副教授和讲师共5人。
三．团队介绍
本团队依托国家细胞调控与分子药物“111”创新学科引智基地及湖北工业大学生物医药研究院等平台。主要研究方向为细胞治疗领域研究，聚焦于：1）新型免疫治疗靶点的发掘；2）增强型细胞治疗产品的开发。在上述研究领域的基础上，团队以临床问题为导向，致力于开发机制清晰、治疗效果显著和安全性强的细胞治疗产品，为重大疾病创新药物的研制提供理论支撑和新的候选产品。团队成员近五年主持国家自然科学基金面上、青年等课题10余项。发表包括Cell metabolism、Nature Cancer、Cell research、Journal of Hematology & Oncology等论文40余篇，总引用超2000次，授权专利10项，完成或参与产业转化项目3项。
四．科研项目
1. 国自然面上项目， 82570226，HOXA13-ASS1轴激活富马酸盐代谢重编程促进T细胞急性淋巴白血病发生发展的机制研究，2026-01至 2029-12，49万元，主持。
2. 国自然青年项目C类，82100193， FGF2-FGFR1信号通路调控T-ALL白血病干细胞的功能及机制研究，2022-01至2024-12，30万元，主持。
3. 国自然青年项目C类， 32601652，肿瘤硫胺素代谢通过重塑微环境调控T细胞功能和机制研究，2027-01至2029-12，30万元，主持。
五. 代表性论文
1.Jiangzhou Shi#, Zijian Zhang#, Hong Cen#, Han Wu, Shangkun Zhang, Jiaxing Liu, Yingqi Leng, Anqi Ren, Xiyu Liu, Zhijie Zhang, Xiqin Tong, Jinjue Liang, Zhe Li, Fuling Zhou, Liang Huang, You Qin, Kunyu Yang, Tongcun Zhang*,Haichuan Zhu*. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.Journal of Hematology & Oncology. 2021.14, 162.
2.Zijian Zhang，Qifang Wu，Anqi Ren，Qian Chen，Jiangzhou Shi，Jiapeng Li，Xiyu Liu，Zhijie Zhang，Yuzhe Tang，Yuan Zhao，Ningning Yao，Xiaoyu Zhang，Changpeng Liu，Ge Dong，Jiaxuan Zhao，Meijun Xu，Yunqiang Yue，Jia Hu，Fan Sun，Yu Liu，Qilin Ao，Fuling Zhou，Hong Wu，Tongcun Zhang*，Haichuan Zhu*.ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming. Acta Pharmacologica Sinica.2023.1-14.
3.Long Chen#, Anqi Ren#, Hangyu Chen, Qifang Wu, Yuan Zhao, Zijian zhang, Tongcun Zhang, Wu Zhong*, Jian Lin*, Haichuan Zhu*, Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL. Journal of Hematology & Oncology. 2023.16(1):113.
4.Yishuang Sun#, Zijian Zhang#, Haiou Li#, Xia Bu#, Li Chen#, Xiyong Wang, Lijun，Kong, Panpan Dai, Wenjing Song, Xiangling Xiao, Jie Shi, Bolin Xiang, Chuan He.GYingmeng Yao, Wenjun Xiong, Haisheng Yu, Congqing Jiang, Hudan Liu, Sufang Tian, Guoliang Qing, Zhiyong Yang, Wenyi Wei*, Gordon J. Freeman*, Haichuan Zhu*, Jinfang Zhang*. Destruction of VISTA by TRlM25 ablation in T cells potentiates cancer immunotherapy. Cell research. 2025.1-18.
5.Yifeng Xiao, Yanling Zhang, Zihao Zhao, Zijian Zhang, Xiaohui Zhang, Pengju Chen, Jin Gu*, Haichuan Zhu*, Peng Jiang*, Jie Cheng*. Aging microenvironment induces CD8+ T cell exhaustion by suppressing hepatic β-hydroxybutyrylate synthesis, Cell Metabolism, 2026. doi:10.1016/j.cmet.2026.08.009.
6.Jie Cheng#,Yifeng Xiao#, Ting Peng#, Zijian Zhang#, You Qin#, Yuqian Wang, Jiangzhou Shi, Jinxin Yan, Zihao Zhao, Liangtao Zheng, Zhijun He , Jianwei Wang, Zemin Zhang*, Cheng Li*, Haichuan Zhu*, Peng Jiang*. (2025). ETV7 limits the antiviral and antitumor efficacy of CD8+ T cells by diverting their fate toward exhaustion. Nature Cancer, 1-19.
7.Jie Chen#, Jinxin Yan#,Ying Liu#, Jiangzhou Shi#, Haoyu Wang, Hanyang Zhou, Yinglin Zhou,Tongcun Zhang,Lina Zhao, Xianbin Meng, Haipeng Gong, Xinxiang Zhang*, Haichuan Zhu*, Peng Jiang*. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment, Cell Metabolism. 2023.35,1-18.
8.Jie Shi#, Zijian Zhang#, Hsin-Yi Chen#, Yingmeng Yao, Shanwen Ke, Kechun Yu, Jiangzhou Shi, Xiangling Xiao, Chuan He, Bolin Xiang, Yishuang Sun, Minling Gao, Xixin Xing, Haisheng Yu, Xiyong Wang,Wei-Chien Yuan,Bugi Ratno Budiarto, ShihYu Chen, Tongcun Zhang, YRu Lee*, Haichuan Zhu*, Jinfang Zhang*. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR T cell therapy. Molecular Therapy. 2025.
9.Haichuan Zhu, Liuzhen Zhang, Yilin Wu, Bingjie Dong, Weilong Guo, Mei Wang, Lu Yang, Xiaoying Fan, Yuliang Tang, Ningshu Liu, Xiaoguang Lei, Hong Wu*, T-ALL leukemia stem cell'stemness' is epigenetically controlled by the master regulator SPI1. Elife. 2018;7: e38314.
六. 联系方式
邮箱：zhuhaichuan@hbut.edu.cn
